| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRANSPROCEED.2004.12.043 |
| P698 | PubMed publication ID | 15848491 |
| P2093 | author name string | Gupta A | |
| Talbot D | |||
| Chapman CE | |||
| Shenton BK | |||
| Turner D | |||
| Carter V | |||
| Jaques B | |||
| Matthews CJ | |||
| Cavanagh G | |||
| P2860 | cites work | Insights into rheumatoid arthritis derived from the Sa immune system | Q24805044 |
| Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection | Q34140501 | ||
| Humoral theory of transplantation | Q35142603 | ||
| Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies | Q46126639 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. | Q50674616 | ||
| Identification of renal podocytes in multiple species: higher vertebrates are vimentin positive/lower vertebrates are desmin positive | Q58438457 | ||
| Capillary deposition of C4d complement fragment and early renal graft loss | Q72791721 | ||
| Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study | Q73278465 | ||
| Increased risk for cardiac allograft rejection in recipients with HLA-B8, DR3 type | Q73667929 | ||
| Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30 | Q74211807 | ||
| Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells | Q74317809 | ||
| Acute rejection is a major risk factor for chronic rejection | Q77176025 | ||
| P433 | issue | 2 | |
| P921 | main subject | risk factor | Q1475848 |
| P304 | page(s) | 654-657 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation | |
| P478 | volume | 37 |
| Q37006610 | Allopeptides and the alloimmune response |
| Q82213207 | Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients |
| Q53245556 | Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody. |
| Q51545645 | Anti-vimentin Antibodies Present at the Time of Transplantation May Predict Early Development of Interstitial Fibrosis/Tubular Atrophy. |
| Q90681771 | Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q35691658 | Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. |
| Q45763669 | Autoimmune Reactivity in Graft Injury: Player or Bystander? |
| Q46310951 | C4d deposition is correlated with the level of antivimentin antibody in rat kidneys undergoing chronic allograft nephropathy |
| Q84238174 | Chronic rejection of human kidney allografts |
| Q38891100 | Clinical value of non-HLA antibodies in kidney transplantation: Still an enigma? |
| Q33551885 | De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection |
| Q47839666 | Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury |
| Q34111522 | Development of antidonor antibody directed toward non-major histocompatibility complex antigens in tolerant animals |
| Q46188986 | Differential Immunogenicity and Clinical Relevance of Kidney Compartment Specific Antigens after Renal Transplantation |
| Q37564586 | Downregulation of vimentin expression increased drug resistance in ovarian cancer cells |
| Q37642331 | Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications. |
| Q58614584 | Extracellular vimentin modulates human dendritic cell activation |
| Q38023423 | Five-year update on the mouse model of orthotopic lung transplantation: Scientific uses, tricks of the trade, and tips for success |
| Q83446805 | Forty years of publication of Transplantation Proceedings--the fourth decade: Globalization of the enterprise |
| Q47800223 | Immunoglobulin isotype switching of antibodies to vimentin is associated with development of transplant glomerulopathy following human renal transplantation |
| Q38123309 | Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection |
| Q37836540 | Loss of tolerance to self after transplant |
| Q36680727 | Pathogenic Network Analysis Predicts Candidate Genes for Cervical Cancer. |
| Q91896945 | Post-translational modifications of vimentin reflect different pathological processes associated with non-small cell lung cancer and chronic obstructive pulmonary disease |
| Q35730607 | Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients |
| Q37286553 | Role of anti-vimentin antibodies in allograft rejection |
| Q26998887 | Significance of T helper 17 immunity in transplantation |
| Q50055232 | Successful Treatment of Anti-angiotensin II Type 1 Receptor Antibody-Associated Rejection in Kidney Transplantation: A Case Report |
| Q38995184 | The Emerging Importance of Non-HLA Autoantibodies in Kidney Transplant Complications |
| Q39122863 | The PROCARE consortium: toward an improved allocation strategy for kidney allografts. |
| Q34106158 | The generation and maintenance of serum alloantibody. |
| Q46894292 | Variability in donor-specific alloantibody production after transplantation. |
| Q27024077 | Vascular endothelium as a target of immune response in renal transplant rejection |
| Q35182104 | Vimentin in cancer and its potential as a molecular target for cancer therapy |
| Q35324023 | Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis |
Search more.